These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 37244231)

  • 1. In-silico method for elucidation of prodigiosin as PARP-1 inhibitor a prime target of Triple-negative breast cancer.
    Sundararajan P; Dharmaraj Rajaselvi D; Vivekananthan S; Priya Ramasamy S
    Bioorg Chem; 2023 Sep; 138():106618. PubMed ID: 37244231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of indole-based natural compounds as inhibitors of PARP-1 against triple-negative breast cancer: a computational study.
    Priyankha S; Rajapandian V; Palanisamy K; Esther Rubavathy SM; Thilagavathi R; Selvam C; Prakash M
    J Biomol Struct Dyn; 2024 Mar; 42(5):2667-2680. PubMed ID: 37154583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemical Characterization,
    Ansari JA; Ahmad MK; Fatima N; Azad I; Mahdi AA; Satyanarayan GNV; Ahmad N
    Anticancer Agents Med Chem; 2022; 22(20):3416-3437. PubMed ID: 35125087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
    Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
    Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual-target platinum(IV) complexes reverse cisplatin resistance in triple negative breast via inhibiting poly(ADP-ribose) polymerase (PARP-1) and enhancing DNA damage.
    Li R; Zhao W; Jin C; Xiong H
    Bioorg Chem; 2023 Apr; 133():106354. PubMed ID: 36720184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
    Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells.
    Chuang HC; Kapuriya N; Kulp SK; Chen CS; Shapiro CL
    Breast Cancer Res Treat; 2012 Jul; 134(2):649-59. PubMed ID: 22678161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of Novel Apigenin-Piperazine Hybrids as Potent and Selective Poly (ADP-Ribose) Polymerase-1 (PARP-1) Inhibitors for the Treatment of Cancer.
    Long H; Hu X; Wang B; Wang Q; Wang R; Liu S; Xiong F; Jiang Z; Zhang XQ; Ye WC; Wang H
    J Med Chem; 2021 Aug; 64(16):12089-12108. PubMed ID: 34404206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis of novel dual target inhibitors of PARP and EGFR and their antitumor activities in triple negative breast cancers.
    Lin S; Zhang X; Yu Z; Huang X; Xu J; Liu Y; Wu L
    Bioorg Med Chem; 2022 May; 61():116739. PubMed ID: 35393219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crystal structure-based discovery of a novel synthesized PARP1 inhibitor (OL-1) with apoptosis-inducing mechanisms in triple-negative breast cancer.
    Fu L; Wang S; Wang X; Wang P; Zheng Y; Yao D; Guo M; Zhang L; Ouyang L
    Sci Rep; 2016 Dec; 6(1):3. PubMed ID: 28442756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of novel PARP-1 inhibitors using tandem
    Bhatnagar A; Nath V; Kumar N; Kumar V
    J Biomol Struct Dyn; 2024 Apr; 42(7):3396-3409. PubMed ID: 37216358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and
    Guleria M; Kumar A; Singh AK; Kumar P
    Comb Chem High Throughput Screen; 2024; 27(9):1329-1343. PubMed ID: 37691193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis of Some Benzimidazole-derived Molecules and their Effects on PARP-1 Activity and MDA-MB-231, MDA-MB-436, MDA-MB-468 Breast Cancer Cell Viability.
    Gurkan-Alp AS; Alp M; Karabay AZ; Koc A; Buyukbingol E
    Anticancer Agents Med Chem; 2020; 20(14):1728-1738. PubMed ID: 32357823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prodigiosin/PU-H71 as a novel potential combined therapy for triple negative breast cancer (TNBC): preclinical insights.
    Anwar MM; Shalaby M; Embaby AM; Saeed H; Agwa MM; Hussein A
    Sci Rep; 2020 Sep; 10(1):14706. PubMed ID: 32895397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, biological evaluation and molecular docking study of novel urea-based benzamide derivatives as potent poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors.
    Lu G; Nie W; Xin M; Meng Y; Gu J; Miao H; Cheng X; Chan ASC; Zou Y
    Eur J Med Chem; 2022 Dec; 243():114790. PubMed ID: 36183505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.
    Yao H; Ji M; Zhu Z; Zhou J; Cao R; Chen X; Xu B
    Bioorg Med Chem; 2015 Feb; 23(4):681-93. PubMed ID: 25614115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantum evaluation and therapeutic activity of (E)-N-(4-methoxyphenyl)-2-(4-(3-oxo-3-phenylprop-1-en-1-yl) phenoxy)acetamide and its modified derivatives against EGFR and VEGFR-2 in the treatment of triple-negative cancer via in silico approach.
    Ipinloju N; Ibrahim A; da Costa RA; Adigun TB; Olubode SO; Abayomi KJ; Aiyelabegan AO; Esan TO; Muhammad SA; Oyeneyin OE
    J Mol Model; 2023 Apr; 29(5):159. PubMed ID: 37099048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of dual PARP and CDK6 inhibitors for triple-negative breast cancer with wild-type BRCA.
    Wang C; Luo H; Chen X; Zhang Y; Lu D; Liu X; Yin F; Li S; Kong L; Wang X
    Bioorg Chem; 2023 Oct; 139():106683. PubMed ID: 37379778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In Silico Discovery of Novel Flavonoids as Poly ADP Ribose Polymerase (PARP) Inhibitors.
    Shah A; Parmar G; Seth AK
    Curr Comput Aided Drug Des; 2021; 17(3):344-350. PubMed ID: 32268868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protein expression of DNA damage repair proteins dictates response to topoisomerase and PARP inhibitors in triple-negative breast cancer.
    Boerner JL; Nechiporchik N; Mueller KL; Polin L; Heilbrun L; Boerner SA; Zoratti GL; Stark K; LoRusso PM; Burger A
    PLoS One; 2015; 10(3):e0119614. PubMed ID: 25774912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.